Ayala Pharmaceuticals (NASDAQ:AYLA) has received a fast-track designation for AL 102 from the U.S. Food and Drug Administration.
AL 102 is a selective oral gamma-secretase inhibitor and has received the fast track designation for the treatment of progressing desmoid tumors.
The drug is currently in a Phase 2/3 trial, RINGSIDE, and has shown positive interim results in Part A, Phase 2 segment of the trial.
Read full Disclosure
